Dr. Simon Ittig, is CEO and Co-founder of T3 Pharmaceuticals AG in Basel, Switzerland, which was awarded the Science Start-up of the Year 2018 at Falling Walls Venture. After studies in biotechnology, Simon completed a PhD on microbial pathogenesis at the Biozentrum in Basel in the framework of the Werner Siemens Excellence fellowships. In May 2015, he co-founded T3 Pharma, which has developed a protein delivery technology based on the use of live bacteria. T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors. For its novel approach on tumor treatment, T3 Pharma has been awarded on multiple occasions.